Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.

Journal of clinical psychopharmacology - 1 Feb 2014

Choi Chang-Ik, Bae Jung-Woo, Lee Yun-Jeong, Lee Hye-In, Jang Choon-Gon, Lee Seok-Yong

Abstract excerpt

Atomoxetine is a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit/hyperactivity disorder. Atomoxetine metabolism is mediated by CYP2D6 and CYP2C19. This study aimed to investigate the effect of the CYP2C19 genetic polymorphism on the pharmacokinetics of atomoxetine and its metabolites, 4-hydroxyatomoxetine and N-desmethylatomoxetine. A single 40-mg oral dose of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Area Under Curve
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Half-Life

Share to Metabolic Clearance Rate

Share to Phenols

Share to Tandem Mass Spectrometry

Source

Identifiers

PMID: 24346747
DOI: 10.1097/JCP.0b013e3182a608a2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.PMID 24346747Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels -- a study based on therapeutic drug monitoring dataSemantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.Semantic proximity Read ↗

Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.Semantic proximity Read ↗

Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.Semantic proximity Read ↗

Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.Semantic proximity Read ↗

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp><i>2D6</i> Genotype and Atomoxetine TherapySemantic proximity Read ↗

Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro.Semantic proximity Read ↗

Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 alleleSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.